The state of Indiana currently has 218 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Indianapolis, South Bend, Fort Wayne and Evansville.
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana
Conditions: Breast Cancer
Rapid Autopsy Protocol for Patients with Small Cell Lung Cancer
Recruiting
This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana +2 locations
Conditions: Small Cell Lung Cancer
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
Recruiting
This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective response rate (ORR). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Ascension St. Vincent, Indianapolis, Indiana
Conditions: Endometroid Endometrial Cancer
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Recruiting
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: St. Vincent Hospital and Health Care Center Inc, Indianapolis, Indiana +1 locations
Conditions: Cervical Cancer
ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
Recruiting
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation therapy (ADT) .
Gender:
MALE
Ages:
40 years and above
Trial Updated:
12/11/2024
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Prostate Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Recruiting
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Community Health Network, Indianapolis, Indiana
Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
Recruiting
This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Metastatic Prostate Cancer
Evaluating Disparities in Precision Oncology
Recruiting
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/24/2024
Locations: Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Metastatic Cancer, Advanced Cancer
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Franciscan Health, Indianapolis, Indiana
Conditions: Myocarditis Acute, Cancer
Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
Recruiting
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the stud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Community Health Network, Indianapolis, Indiana +1 locations
Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
ATEMPT 2.0: Adjuvant T-DM1 Vs TH
Recruiting
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Indiana University Health Joe & Shelly Schwarz Cancer Center, Carmel, Indiana +3 locations
Conditions: Breast Cancer, HER2-positive Breast Cancer
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
Recruiting
Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Ferring Investigational Site, Greenwood, Indiana +1 locations
Conditions: Bladder Cancer